Drug Database
ER

erythromycin (Erymin / erythromycin, Elan)

✓ Approved

Takeda · Small Molecule · Small Molecule

What is erythromycin?

erythromycin is a small molecule developed by Takeda. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesErymin, erythromycin, Elan
CompanyTakeda
Drug ClassSmall Molecule
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Takeda

Therapeutic Indications

erythromycin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsSalmonellosis✓ Approved

Related Research Articles

PubMedMolecules (Basel, Switzerland)2026-10-16

Development of an LC-MS/MS Method for Simultaneous Quantification of Erythromycin A and Seven Metabolites: Initial Residue Profile in Salmon Muscle with Skin.

Chattopadhaya Chaitali C, Knutson Sean S, Escobar Loaiza Hernando H, Taylor Kenneth M KM et al.

A robust liquid chromatography tandem mass spectrometry (LC-MS/MS) method was developed and validated for determining erythromycin A (ERY A) and its metabolites: erythromycin B (ERY B), erythromycin C (ERY C), erythromycin A N-oxide (ENO), anhydroerythromycin A (AHEA), N-demethylerythromycin A (NDEA), erythromycin A enol ether (EAEE), and pseudoerythromycin A enol ether (PSEE) in salmon muscle with skin. Tissue samples (1.00 g) fortified with ERY A, ERY B, ERY C, ENO, EAEE, and PSEE at 50-200 ng/g and AHEA and NDEA at 500-2000 ng/g, using a surrogate internal standard, were extracted with acetonitrile, defatted hexane, and diluted water, resulting in accuracy from 87% to 108%, precision from 3% to 13%, and estimated LOQ from 0.02 to 1.2 ng/g. Incurred salmon showed ERY A as the major residue at 3 days post-administration and NDEA and AHEA as potential markers exceeding the 500 ng/g level on Day 28.

PMID 42883172
Read full article →
PubMedInternational journal of molecular sciences2026-10-16

Characteristics of Staphylococcus epidermidis Isolated from Humans and Animals.

Prorok Paulina P, Siedlecka Magdalena M, Karwańska Magdalena M, Skrok Milena M et al.

Staphylococcus epidermidis is an important opportunistic pathogen and a potential reservoir of antimicrobial resistance determinants, yet comparatively little is known about isolates originating from both humans and companion animals. This study characterized 320 S. epidermidis isolates obtained from humans, cats, and dogs within a One Health framework using phenotypic, molecular, proteomic, and genomic approaches. Antimicrobial susceptibility testing revealed high frequencies of resistance to oxacillin (67.19%), erythromycin (66.56%), tetracycline (55.63%), and clindamycin (53.75%) by disk diffusion. PCR-based analysis identified blaZ as the most prevalent resistance determinant (50.63%), whereas whole-genome sequencing of a selected subset revealed a broader and heterogeneous repertoire of resistance-associated genes. Among 67 sequenced isolates, 26 known sequence types were identified, including several STs occurring in isolates from more than one host species. Core-genome phylogenetic analysis demonstrated substantial genomic diversity without complete segregation according to host species or clinical status. Genotype-phenotype concordance was generally limited and gene dependent, and discrepancies were also observed between PCR- and WGS-based detection for selected resistance determinants. Biofilm formation was significantly influenced by incubation temperature, host species, and clinical status, while growth kinetics showed pronounced strain-specific variability and no consistent relationship with biofilm-forming capacity. MALDI-TOF MS profiling and partial rpoB phylogeny likewise showed considerable overlap among isolates from different host groups. In the Galleria mellonella infection model, mortality was inoculum dependent and varied substantially among strains. Overall, the findings demonstrate marked phenotypic and genomic heterogeneity among S. epidermidis isolated from humans and companion animals and indicate that some clonal backgrounds and resistance determinants occur across host species, highlighting the relevance of this species within a One Health context.

PMID 42883836
Read full article →
PubMedFrontiers in cellular and infection microbiology2026-10-15

Genomic and antimicrobial susceptibility characterization of a clinical Pasteurella aerogenes isolate from a human patient.

Chen Ying Y, Brandis Gerrit G, Li Hong H, Luo Yongjun Y et al.

Pasteurella aerogenes is an opportunistic zoonotic pathogen associated with reproductive disorders in animals and sporadic human infections. However, the complete genome, antimicrobial susceptibility profile, and phylogenetic relationships of clinical P. aerogenes isolates, particularly from China, remain poorly understood. We sequenced the complete genome of the clinical P. aerogenes isolate 21PA20240911 from a patient with urinary tract infection in Hainan, China, using a hybrid PacBio and Illumina sequencing approach. Comparative genomic analyses, including genome feature characterization, ANI-based species delineation, virulence gene screening, antimicrobial susceptibility testing, and cgSNP-based phylogenetic analysis, were performed to investigate the strains genomic landscape and evolutionary origin. The genome of strain 21PA20240911 was 2.3Mbp with a G+C content of 40.84%. ANI analysis confirmed its taxonomic assignment as P. aerogenes (97.61% identity with the reference strain). The strain carried 28 virulence-associated genes. Notably, tviB and wbpD were detected only in our strain and a duck-derived Sichuan isolate. The isolate was resistant only to erythromycin but showed nonsusceptibility to multiple β-lactams and tetracyclines. Resistance-associated determinants included tet (B)/tetR and a putative PBP3/FtsI-like protein variant carrying D350N and S357N substitutions. Phylogenetic analysis tentatively suggests the possibility of zoonotic transmission from local poultry for this strain. This study provides the first complete genome sequence of a clinical P. aerogenes isolate from China, offering a genomic foundation for understanding its pathogenicity and antimicrobial resistance. From a One Health perspective, enhanced surveillance in both clinical and veterinary settings is warranted.

PMID 42876705
Read full article →
PubMedRevista Argentina de microbiologia2026-10-14

Antimicrobial resistance and antibiotic therapy in patients with urinary tract infections and asymptomatic bacteriuria: A Peruvian perspective.

Castilla-Torres Nancy V NV, Castilla Jeanette J, Apayco-Espinoza Nilda A NA, Urrutia-Zegarra Alexandra A AA et al.

Overdiagnosis and overtreatment of urinary tract infections (UTIs) and asymptomatic bacteriuria (AB) increase antimicrobial resistance. The aim of this study was to evaluate resistance patterns and antibiotic therapy in patients with UTIs and AB in Peru. Cross-sectional study based on 164 urine cultures and antimicrobial susceptibility testing. A total of 62 cases of AB and 102 of UTI were identified. Women (116, 70.7%) and older adults (60, 36.6%) predominated. A total of 4582 antibiotic prescriptions were recorded, with a therapeutic pattern in both UTI and AB centered on the use of meropenem (540, 21.3%) and (333, 16.3%), vancomycin (221, 8.7%) and (454, 22.2%), ceftriaxone (369, 14.5%) and (176, 8.6%) and ceftazidime (227, 8.9%) and (274, 3.4%), respectively. In general, antibiotic therapy was bactericidal in (87, 53.0%) cases, from the surveillance group in (98, 59.8%) cases, monotherapy in (112, 68.3%) cases, and in cycles of ≤7 days. UTI was associated with a higher burden of comorbidities, including chronic renal failure, hypertension, and diabetes. Fifteen bacterial species were isolated in both clinical entities, with a predominance of Gram-negative bacilli, mainly Escherichia coli and Klebsiella pneumoniae, both of which exhibited high resistance to cephalosporins, sulfonamides, and ampicillin/sulbactam. Among Gram-positive bacteria, Enterococcus faecalis and E. faecium showed resistance to erythromycin, tetracycline, and quinolones. The widespread use of antibiotics from the surveillance group and similar antibiotic therapy in AB and UTI, revealed a critical gap in the implementation of clinical guidelines and the urgent need to accurately differentiate between the two diagnoses to avoid overprescribing and help contain bacterial resistance.

PMID 42874358
Read full article →
PubMedMatrix biology : journal of the International Society for Matrix Biology2026-10-14

Clitocine for Translational Readthrough in Junctional Epidermolysis Bullosa.

Zhang Rui R, Mabrouk Haifa El HE, Has Cristina C, Sayar Saliha Beyza SB

Junctional epidermolysis bullosa (JEB) caused by laminin-332 deficiency (JEB-LAM332) is a severe inherited skin disorder characterized by impaired dermal-epidermal adhesion, chronic wounds, and increased cancer susceptibility. The management of JEB-LAM332 is primarily symptomatic, focusing on wound care and general supportive measures; however, many therapeutic needs remain unmet. While gene and stem cell therapy has been effective in JEB-LAM332, it is not yet broadly available owing to its complexity and cost. Translational readthrough-inducing drugs (TRIDs) represent an alternative strategy for treating JEB-LAM332, given that most patients carry nonsense mutations in at least one allele of their LAMA3, LAMB3, or LAMC2 genes, with LAMB3 c.1903C>T, p.R635* (p.Arg635Ter) being the most common variant. To determine promising TRID candidates for developing readthrough therapy for JEB-LAM332 patients with LAMB3 mutations, we evaluated different classes of TRIDs and compared their efficacy against gentamicin. Erythromycin, TRID-C5 (aminoglycoside-based cocktail), artesunate and atazanavir (non-aminoglycosides, ribosomal protein RpL35 ligand) and clitocine (nucleoside analog) were tested in patient-derived keratinocytes carrying the LAMB3 nonsense variants, homozygous c.1903C>T (p.R635*) or compound heterozygous c.124C>T;c.1903C>T (p.R42*;p.R635*). We used a previously established screening platform for systematic testing of TRIDs, including immunoblotting, cell functional assays, and transcriptomics. We identified clitocine as the most potent compound for promoting translational readthrough, restoring laminin β3 chain expression and improving keratinocyte adhesion in JEB models. Clitocine treatment elicited dose- and mutation-dependent responses, while toxicity was observed at higher concentrations, particularly in normal keratinocytes. Although normal keratinocytes are not the intended therapeutic target, these findings highlight the importance of defining a therapeutic window and optimizing mutation-specific dosing. Overall, clitocine represents a potential candidate for the topical therapy of JEB-LAM332.

PMID 42874790
Read full article →
PubMedFrontiers in microbiology2026-10-13

Genomic insight into the antibiotic-resistant determinants of Escherichia coli from small ruminants and manure in North West Province, South Africa.

Howard Jody J, Thekisoe Oriel O, Ramatla Tsepo T, Lekota Kgaugelo E KE

Livestock-associated Escherichia coli are important reservoirs of antimicrobial resistance and virulence determinants, yet comprehensive genomic data describing their genomic diversity and antibiotic resistance in South African small-ruminant production systems remain limited. Whole-genome sequencing was performed on 19 E. coli isolates recovered from sheep, goats, and manure collected from two farming systems in the North West Province, South Africa. Genomic analyses revealed a dual pattern of clonal expansion and deep heterogeneity, with globally distributed sequence types (ST10, ST155) occurring alongside several novel or rarely reported STs. Comparative genomic analyses incorporating average nucleotide identity (ANI), multilocus sequence typing (MLST), in silico serotyping, antimicrobial resistance profiling, virulence characterization, and mobile genetic element analysis revealed substantial genomic diversity, comprising globally disseminated sequence types, including ST10 and ST155, together with several novel and infrequently reported lineages. Although most isolates (n =17) belonged to phylogroups A and B1, the resistome was dominated by the multidrug efflux gene mdf(A) (95%) and bla TEM - 1B (58%), corresponding with high phenotypic resistance to erythromycin (74%) and ampicillin (95%), while 26% of isolates exhibited multidrug-resistant phenotypes. Genomic analysis identified 71 plasmids representing diverse incompatibility groups and mobility classes, including conjugative and mobilizable IncHI1B and IncR plasmids carrying clinically relevant resistance genes. Approximately 89% belonged to commensal lineages (A and B1), while groups D and E were each represented by a single isolate. To our knowledge, this represents the first whole-genome sequencing-based genomic characterization of E. coli recovered from sheep and goats in South Africa, thereby expanding the known genomic diversity of livestock-associated E. coli within the country. Furthermore, data generated in this study emphasizes the necessity of ongoing genomic monitoring to track the emergence and spread of resistant E. coli, which is crucial for monitoring and mitigating potential public health risks.

PMID 42865510
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about erythromycin